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ABSTRACT
Introduction: The global burden of cirrhosis is rising, and clinicians increasingly face the challenge of
safely prescribing medicines for complications of hepatic disease and comorbidities. Prescribing in
patients with cirrhosis is complicated by alterations that can occur in the pharmacology of medicines.
Areas covered: This paper provides an overview of current knowledge on the pharmacokinetics and
pharmacodynamics of medicines in patients with cirrhosis. We describe the pathophysiological changes
that occur and their consequences on pharmacokinetic parameters. We explain that the influence of
cirrhosis on the pharmacokinetics depends on several drug and patient characteristics. Patients with
cirrhosis also have an increased susceptibility to some toxicological effects of medicines, such as renal
impairment and hematological toxicity, which we describe in detail. In addition, we discuss approaches
to apply this knowledge in practice and improve safe medication use in patients with cirrhosis.
Expert opinion: Tailored pharmacotherapy is needed to ensure safe and appropriate use of medicines
in patients with cirrhosis. Clinicians are supported by freely available recommendations on safe drug
use in cirrhosis published on a website. In addition, a regular evaluation of medication use in patients
with cirrhosis could resolve and prevent medication-related problems.
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Clinicians increasingly face the challenge of safely prescribing
medicines in patients with cirrhosis due to the rising burden of
chronic liver disease [1]. Over the past decades, the global
mortality of cirrhosis has increased to over 1 million deaths
annually [2,3]. The most prevalent causes of cirrhosis in Europe
are chronic alcohol use disorder, viral hepatitis B (HBV) and
C (HCV) infection, and nonalcoholic steatohepatitis (NASH) [4].
All these chronic liver diseases share a similar hepatitis-fibrosis
sequence to cirrhosis [5,6]. Regardless of etiology, injury to
hepatic tissue can trigger an inflammatory reaction known as
hepatitis. Upon progression, scar tissue ensues: fibrosis. While
early fibrosis is often asymptomatic, advanced fibrosis or ‘cir-
rhosis’ is associated with increasing loss of hepatocyte density
and function, formation of scar tissue with regenerative
nodules, and intrahepatic resistance to blood flow [5]. This
leads to an increase in portal vein pressure followed by the
clinical consequences of portal hypertension.
In the clinical setting, cirrhosis in the absence of complica-
tions is termed ‘compensated.’ However, silent progression of
portal hypertension and hepatocellular dysfunction can lead
to the development of a rapidly progressive ‘decompensated’
phase, which is characterized by debilitating complications
including ascites, hepatic encephalopathy (HE), jaundice, and
bleeding [5]. Increasing hepatocyte dysfunction affects several
of the metabolic and synthetic functions of the liver [7] includ-
ing metabolism of endogenous (e.g. bilirubin) and exogenous
substances (e.g. medication). Impaired detoxification can lead
to accumulation of neurotoxins and contribute to develop-
ment of HE. Cirrhosis also affects the synthesis of plasma
proteins, such as albumin and coagulation factors. Reduced
serum albumin and alterations in splanchnic circulation driven
by portal hypertension can lead to fluid accumulation in the
abdomen (i.e. ascites) [5,7]. Portal hypertension can further
result in the development of portosystemic collaterals and
esophageal or gastric varices [5,7], which come with a risk of
bleeding.
The presence of cirrhosis and its complications can result in
clinically important changes in the pharmacokinetics (PK) and
pharmacodynamics (PD) ofmedicines. This can have implications
for medication safety as there is an increased risk of adverse drug
reactions (ADRs) and patient harm. A cross-sectional study of 400
cirrhotics admitted to a Swiss hospital showed that almost 30%
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suffered from ADRs [8,9]. Furthermore, of the 210 ADRs noted in
this study, the authors judged 78% as probably preventable
because of the use of excessively high dosages or contraindi-
cated medicines [9]. To prevent ADRs, patients with cirrhosis
should receive pharmacotherapy tailored to the changes in
both PK and PD.
This paper provides an overview of current knowledge on
the pharmacology (i.e. PK and PD) of medicines in patients
with cirrhosis. In addition, we describe approaches to improve
safe medication use in patients with cirrhosis in practice and
identify areas for further research.
2. Pharmacokinetic changes
Table 1 describes several pathophysiological changes that may
occur in cirrhosis and the consequence of these changes on
PK parameters [10–13]. These changes could lead to decreased
plasma levels of medicines, for example due to diminished
prodrug activation or disrupted enterohepatic recycling.
However, PK alterations in patients with cirrhosis most fre-
quently result in increased exposure to medicines. The extent
of these increases depends on both drug and patient charac-
teristics [14].
2.1. Drug characteristics
The characteristics of a medicine and its route of administra-
tion should be taken into consideration when examining the
potential impact of altered PK in patients with cirrhosis.
2.1.1. Pharmacokinetic characteristics
As presented in Table 1, all PK parameters may be affected by
cirrhosis. To explain the outcome of these changes on drug plasma
levels, the well-stirred model is frequently used [11,13,14]. This
model assumes that hepatic drug clearance depends on three
factors: (1) hepatic blood flow, (2) the hepatocytes’ ability to meta-
bolize a medicine (intrahepatic clearance), and (3) the fraction of
unboundmedicine [11,13,14]. Thehepatic extraction ratio (EH) is the
fraction of drug cleared from the blood during a single passage
through the liver. In the well-stirred model, medicines are classified
by their hepatic extraction ratio into: high (EH>0.7), intermediate (EH:
0.3–07), and low (EH<0.3) extraction drugs [11].
For drugs with a high EH, the liver is very efficient in clearing the
medicine from the blood. Therefore, hepatic blood flow is the factor
limiting hepatic clearance (‘flow-limited’). These medicines usually
undergo substantial first-pass metabolismwhen orally administered
in healthy patients [13]. However, in patients with cirrhosis, patho-
physiological changes that affect blood flow, such as the develop-
ment of portosystemic shunts, can have a large influence on
circulating drug plasma levels. An example of this is the medicine
naltrexone, which has a bioavailability of 5–40% in healthy indivi-
duals. Exposure to naltrexone is approximately fivefold higher in
compensated, and tenfold higher in decompensated cirrhosis, com-
pared to healthy controls [15], likely explained by a diminished first-
pass effect.
For drugs with a low EH, the liver is less efficient in clearing
medicines from the blood. Therefore, drug clearance is predo-
minantly influenced by intrinsic hepatic clearance and the free
fraction of the medicine (‘capacity-limited’). These medicines
are sensitive to changes in plasma protein binding (if highly
protein bound) and reduced metabolic enzyme activity.
Examples of low EH medicines include proton pump inhibitors
(PPIs), lansoprazole and pantoprazole. Exposure to both medi-
cines is largely increased in patients with cirrhosis, which results
from a decrease of CYP2C19 enzyme activity in cirrhosis [16].
At last, the hepatic clearance of medicines with an inter-
mediate EH depends on all the three factors (i.e. hepatic blood
flow, hepatic metabolic activity and fraction of unbound med-
icine). An example of such a medicine is paroxetine. In
patients with cirrhosis, a doubled exposure to paroxetine has
been seen after multiple-dosing [17].
Gonzales and colleagues used data from 84 published pharma-
cokinetic studies to describe the relationship between certain drug
characteristics (including EH) and the extent of PK alterations in
patients with cirrhosis [18]. In subjects with moderate and severe
hepatic impairment, a trend toward a higher exposure tomedicines
with higher EH ratios was found. However, the clinical meaning of
this finding is uncertain as some medicines with a low EH also
exhibitedmajor increases in exposure. The only significant negative
predictor for large PK alterations was extensive renal elimination. If
more than 40%of amedicinewas excreted unchanged in the urine,
the predicted increase in exposure was less than twofold. Yet, this
finding should be interpreted with caution since patients with
severe cirrhosis may also suffer from (covert) renal impairment
[11]. Furthermore, the administration route of the study drugs was
not considered as a variable, whichmay also influence the extent of
PK changes in cirrhosis.
2.1.2. Route of administration
As a result of hemodynamic changes in cirrhosis, portosystemic
shunts may develop. The consequence is that medicines may
be less exposed to the first-pass effect of the liver and drug
bioavailability can substantially increase. All administration
routes that are subjected to the first-pass effect can be
impacted, with the greatest effect on medicines with a high EH.
The difference in PK changes between oral and parental
administration in cirrhosis has been demonstrated for several
medicines. Coting and colleagues [19] found a fourfold greater
exposure to isradipine following oral administration, and
a twofold increase following intravenous administration in
patients with cirrhosis versus healthy controls, respectively.
The biological availability of oral isradipine increased from
17% in healthy patients to 37% in the patients with cirrhosis
Article highlights
● Cirrhosis may affect all pharmacokinetic parameters, which can result
in an increased plasma drug concentration. The extent of increase
depends on both drug (e.g. pharmacokinetic properties and the
administration route) and patient characteristics (e.g. the etiology
and severity of cirrhosis).
● Patients with cirrhosis may have an increased susceptibility to the
toxicological effects of medicines due to pathophysiological changes.
● Health-care professionals should anticipate these pharmacokinetic
and pharmacodynamic changes and can be supported by recommen-
dations for safe prescribing in cirrhosis.
This box summarizes key points contained in the article.
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[19]. Increased bioavailability has also been demonstrated
with nifedipine, an intermediate EH drug. Kleinbloesem and
colleagues showed oral bioavailability was around 50% in
healthy controls and increased to 90% in patients with cirrho-
sis [20]. Exposure to oral naltrexone also increases substan-
tially in cirrhosis (fivefold and tenfold increase in patients with
compensated and decompensated cirrhosis, respectively)
compared to healthy controls [15]. After intramuscular injec-
tion, the pharmacokinetics of naltrexone in patients with mild
and moderate cirrhosis was not different from that of healthy
controls [21], although data in patients with severe cirrhosis is
lacking.
Theoretically, an increase in bioavailability following rectal
administration could also occur, yet no pharmacokinetic stu-
dies could be found that examined this.
2.2. Patient characteristics
Characteristics of people with cirrhosis can further influence
the PK changes that occur [14]. Such patient characteristics
include the severity of cirrhosis, the presence of a transjugular
intrahepatic portosystemic shunt (TIPS) and (possibly) the type
of underlying liver disease. In addition, some other character-
istics such as nutritional status and genetic polymorphisms
may also impact the PK changes that occur.
2.2.1. Severity of cirrhosis
Progression of the underlying liver disease can lead to dete-
rioration of liver function and progression of cirrhosis compli-
cations, which can further influence PK changes. For example,
a (differential) decline in the activity of almost all metabolizing
enzymes has been demonstrated with increasing severity of
cirrhosis [10,11]. This often results in increased drug plasma
levels and greater exposure to medicines [22–26]. Additionally,
with increasing severity of cirrhosis, renal function frequently
also declines [5].
To assess the severity and prognosis of cirrhosis, the Child–
(Turcotte)–Pugh classification is commonly used in clinical
practice [27,28]. Registration authorities also demand to use
the Child-Pugh classification for categorizing patients by
severity of hepatic dysfunction in pharmacokinetic studies
with new medicines [29,30]. That is why product labels
Table 1. Overview of pathophysiological abnormalities that can occur in patients with cirrhosis and the consequences on pharmacokinetic
parameters.
Pathophysiological change Pharmacokinetic change
Absorption ● Portal hypertensive gastropathy, ulcers of the upper
gastrointestinal tract, gastritis
● Increased intestinal permeability
● Impaired gastrointestinal motility with delayed gastric
emptying
● Altered extent of drug absorption
● Decreased rate of absorption
● Altered hepatic blood flow (e.g. portosystemic shunts,
TIPS)
● Reduced intrinsic clearance
● Decreased first-pass effect resulting in a higher bioavailability
● Pro-drug metabolism diminished
Distribution ● Decreased levels of plasma proteins (e.g. albumin, α1-
acid glycoprotein) due to impaired synthesis in the
liver
● Accumulation of endogenous substances, such as
bilirubin, displacing binding sites of plasma proteins
● Fluid retention (ascites, edema)
● Reduced plasma protein binding resulting in a larger fraction of
unbound drug
● Enlarged volume of distribution
Metabolism ● Alterations in hepatic architecture including
hepatocellular necrosis, altered blood flow, and
nodular formation
● Reduced activity or expression of phase I and II drug-metabolizing
enzymes (reduced intrinsic clearance). The extent of reduced activity
differs per enzyme. Some enzymes are very sensitive for these
pathophysiological changes (e.g. CYP2C19), while others are affected
in a later stage (e.g. CYP2D6).
● Changes in stereoselectivity of hepatic drug metabolism
● Reduced blood flow across the liver ● Delayed clearance by drug-metabolizing enzymes
Elimination ● Bile flow obstruction, due to cancer or sclerosing
cholangitis
● Reduced protein transporter expression
● Biliary excretion reduced
● Disrupted enterohepatic recycling
● In advanced cirrhosis, renal impairment ● Reduced renal elimination
TIPS: transjugular intrahepatic portosystemic shunt
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commonly provide dosing recommendations based on Child-
Pugh class [31]. However, the Child-Pugh classification was not
developed for this purpose and appropriate use of the score in
clinical practice is essential to enable interpretation. For exam-
ple, the Child-Pugh classification should not be used to screen
for hepatic impairment, as individual parameters are not spe-
cific for hepatic dysfunction. Bilirubin can be increased due to
hemolysis or Gilbert’s syndrome, and albumin decreased due
to sepsis [27]. In addition, if the Child-Pugh score is calculated
in persons without cirrhosis they will all be categorized as
‘mild hepatic impairment’ because that is the minimum
score [27].
In older literature, often no distinction was made in the
severity of cirrhosis of the participants, which could have
affected the PK changes that were found. For example, in
a study from 1993, fluvoxamine was administered to 13
patients with cirrhosis, not specified by severity. An increase
in exposure of 50% in the patients with cirrhosis was found
compared to healthy controls [32]. Comparatively, a more
recent work that studied both patients with Child–Pugh
A cirrhosis and Child-Pugh C cirrhosis demonstrated an expo-
sure increase of 50% and 150%, respectively, compared to
healthy controls [24].
2.2.2. TIPS
If the complications of portal hypertension get too severe (e.g.
refractory ascites, recurrent or uncontrolled variceal bleeding),
a TIPS could be placed to decrease portal pressure by con-
necting the portal vein to the hepatic vein [6,7]. This can
particularly affect the first-pass metabolism, yet the influence
of TIPS on PK has only been limitedly studied. A study with
midazolam demonstrated that in patients with cirrhosis and
a TIPS, plasma levels after oral administration were 1.5 times
higher than in cirrhosis without a TIPS [33]. In addition, a case-
report described the toxicity of beta-blockers and diltiazem
after TIPS placement [34]. All these medicines have a high or
intermediate EH and are therefore sensitive to changes in
blood flow caused by TIPS. On the other hand, in a patient
with Child–Pugh A cirrhosis, only a minor elevation in peak
plasma levels of caspofungin was noted after TIPS placement
[35], comparable to Child–Pugh A patients without a TIPS. It
has been estimated that caspofungin has a low EH [18]. Hence,
TIPS placement will likely have a greater influence on the
plasma levels of orally administered medicines with high and
intermediate EH.
2.2.3. Etiology of cirrhosis
The underlying type of hepatic disease could potentially affect
the extent of PK changes via altered expression and activity of
drug-metabolizing enzymes. One study documented that the
cause of cirrhosis (hepatocellular or cholestatic) results in dif-
ferences in CYP-enzyme expression [36]. A recent article by
Prasad and colleagues assessed the abundance of metabolic
enzymes in livers from transplanted patients with Child-Pugh
C cirrhosis caused by alcohol versus HCV. In general, the
abundance of most enzymes in cirrhotics is reduced to
25–50% compared to healthy livers [37]. In particular, cirrhotic
livers affected by alcohol have profoundly lower alcohol
dehydrogenase 1A and 1B and UGT1A4 compared to cirrhosis
caused by chronic hepatitis C [37].
Studies have compared the actual effect of different etiol-
ogies of cirrhosis on drug plasma levels and clearance of
substances. In a work by Breimer and colleagues [14], clear-
ance of antipyrine (low EH) was compared between groups of
patients with different underlying causes and severity of the
liver disease. Patients with alcoholic cirrhosis had the lowest
clearance, yet overlap existed with the group of patients with
a primary biliary cirrhosis, those with cryptogenic cirrhosis
and those with chronic active hepatitis. A study with the
bile acid glycocholic acid (high EH) compared clearance
between groups of patients with acute hepatitis (viral/alco-
holic), chronic viral hepatitis, alcoholic/cryptogenic cirrhosis,
primary biliary cirrhosis and healthy controls [38]. Clearance in
the two cirrhosis groups was significantly decreased com-
pared to controls and the hepatitis groups, but no differences
between the groups with cirrhosis were found. The presence
of jaundice was an important confounder, most likely reflect-
ing the severity of hepatic impairment. Therefore, while the
expression and activity of enzymes may differ between types
of liver disease underlying cirrhosis, the clinical implications of
altered plasma drug levels are uncertain.
2.2.4. Other patient characteristics
There are also other patient characteristics that may influence
the pharmacokinetics of medicines in patients with cirrhosis,
such as nutritional status and genetic polymorphisms. Cirrhotic
patients are often malnourished [6], especially in decompen-
sated cirrhosis and this may affect paracetamol pharmacoki-
netics [39,40]. A small proportion of paracetamol is metabolized
by CYP2E1 to the hepatotoxic intermediate N-acetyl-p-benzo-
quinone imine (NAPQI). Glutathione detoxifies NAPQI.
Malnourishment may lead to lower glutathione levels and the-
oretically a higher risk of hepatotoxicity [39,41]. Yet, in patients
with cirrhosis, the outcome is difficult to predict because
CYP2E1 activity is possibly already decreased with less NAPQI
formed. In addition, another factor that may affect paracetamol
pharmacokinetics is (chronic) use of alcohol. This can induce
CYP2E1 and consequently NAPQI formation [39]; however, this
has not been demonstrated in cirrhotic patients [41].
Genetic polymorphisms affect the activity of drug-
metabolizing enzymes. There is a paucity of data on the
combined influence of cirrhosis and genetic polymorphism
on medicine clearance. The most comprehensive study was
performed by Ohnishi and colleagues and compared
CYP2C19 activity in healthy controls and patients with cir-
rhosis using the omeprazole hydroxylation index [42]. They
found that CYP2C19 activity in healthy controls with a poor
metabolizer (PM) genotype was comparable to the CYP2C19
activity of cirrhotic patients with a heterozygous and homo-
zygous extensive metabolizer genotype. The hydroxylation
index of patients with a PM genotype was significantly
higher than these groups, suggestive of an even lower
CYP2C19 activity. Another study demonstrated that exposure
to pantoprazole in patients with Child-Pugh B and C cirrhosis
was comparable to healthy controls that were PM of
CYP2C19 [43]. The authors did not determine the genotype
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of cirrhotic patients. Two articles assessed the influence of
CYP2D6 polymorphism on the hemodynamic effect of pro-
pranolol in patients with cirrhosis [44,45]. The study by
Zhang and colleagues [45] found that a specific CYP2D6
genotype (188C>T) was a predicting factor for hemodynamic
response to propranolol, while the other article did not find
a polymorphism related to response [44]. Both studies did
not compare their results to a control group of subjects
without cirrhosis.
3. Pharmacodynamic changes
Patients with cirrhosis may respond differently to the same
medicine plasma concentrations as healthy persons. This is
explained by changes in the number and sensitivity of recep-
tors or the access of medicine to the site of action. This could
result in a diminished or more pronounced therapeutic effect,
including potential toxicity in patients with cirrhosis.
3.1. Altered pharmacological effect
There is a paucity in the literature on changes in the thera-
peutic effect of medicines in patients with cirrhosis. Most
research to date has focussed on diuretics, beta-blockers,
muscle relaxants, and renin-angiotensin-aldosterone system
(RAAS) inhibitors. A diminished response to diuretics such as
furosemide and torsemide, independent of PK changes, has
been demonstrated [46–49]. This could be related to reduced
diuretic potential of the nephrons and/or a reduced number of
nephrons [46]. After a single dose of the beta-blocker meti-
pranolol, a less pronounced effect on heart rate was demon-
strated in patients with cirrhosis compared to healthy controls
[50]. The authors suggest that due to chronic sympathetic
activation, downregulation of beta-adrenoreceptors could
occur [50]. However, a recent study revealed that the response
to propranolol was dose-dependent and not different to
healthy controls when controlled for the PK alterations that
occur in cirrhosis [51]. The effect of cirrhosis on the response
to muscle relaxants has been relatively well studied [52–59].
All these studies demonstrated that if differences occurred in
pharmacological response, these were correlated with differ-
ences in PK parameters. Therefore, sensitivity to the effect of
muscle relaxants seems to be comparable to healthy controls.
The evidence on the pharmacological response to RAAS-
inhibitors in patients with cirrhosis is conflicting. Several stu-
dies demonstrated that the percentage of angiotensin-
converting enzyme (ACE) inhibition in cirrhosis was not differ-
ent than in healthy controls [60–63]. One found a largely
decreased activation of enalapril to its active form in patients
with cirrhosis, yet the effect on blood pressure was similar to
the healthy controls suggesting that the patients are more
sensitive to this effect [61].
3.2. Altered toxicological effect
Patients with cirrhosis could have an increased susceptibility
to the toxicological effects of medicines. Croxen and collea-
gues previously published a comprehensive overview of unde-
sirable side effects in patients with liver disease [64]. Figure 1
provides an overview of the pathophysiological changes in
cirrhosis that may contribute to an increased risk of ADRs in
patients with cirrhosis.
3.2.1. Renal impairment
Studies involving nonsteroidal anti-inflammatory drugs
(NSAIDs) [65,66] demonstrated a significant decrease in the
mean glomerular filtration rate of around 30% in patients with
cirrhosis following the use of a NSAID. In another paper, 50%
Figure 1. Overview of toxicological effects that patients with cirrhosis seem to be more susceptible to compared to healthy controls and underlying pathophy-
siological changes.
ADR: adverse drug reaction, GI: gastro-intestinal, PPIs: proton pump inhibitors, NSAIDS: non-steroidal anti-inflammatory drugs, RAAS: renin-angiotensin-aldosterone system
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of patients with cirrhosis using ibuprofen-developed renal
impairment [67]. RAAS-inhibitor use has also been linked to
the development of renal dysfunction in patients with decom-
pensated cirrhosis [68]. In 18 patients with a history of ascites,
4 (22%) suffered from (transient) renal impairment after irbe-
sartan use [69]. There are several ways in which medicines can
induce renal impairment in patients with cirrhosis.
Cirrhosis-driven interference with renal hemodynamics has
been well described [70]. Alteration in systemic hemody-
namics occurs in patients with cirrhosis as progressive portal
hypertension causes splanchnic vasodilation. To preserve renal
function, the RAAS system is activated leading to excretion of
renal vasodilators for the afferent arterioles (e.g. prostaglan-
dins) and vasoconstrictors for the efferent arterioles (e.g.
angiotensin-II (AT-II)) [71]. Medicines that interfere with this
mechanism, such as RAAS-inhibitors and NSAIDs (by inhibiting
AT-II and prostaglandin synthesis, respectively) could lead to
acute renal impairment [70].
Another mechanism by which medicines may induce renal
impairment is by a direct toxic effect on tubular cells [70]. Of
note, these cells are also involved in the metabolism of pros-
taglandins [70,72]. Aminoglycosides are medicines that cause
nephrotoxicity by this mechanism, and renal impairment was
more frequent in patients with underlying liver dysfunction
compared to healthy controls or patients receiving a different
antibiotic [72,73]. Both studies described four to five times
higher odds for developing aminoglycoside-associated renal
impairment among patients with preexisting hepatic dysfunc-
tion. It is unknown whether this was caused by tubular toxi-
city, interference with prostaglandin metabolism, or
a synergistic toxic effect.
3.2.2. Neurotoxicity
Another well-known risk in patients with cirrhosis is the poten-
tial for neurotoxicity (e.g. confusion, HE) with certain medi-
cines. A recent work by Bajaj and colleagues demonstrated the
significant role of medicines in precipitating HE [74]. Among
2810 patients with cirrhosis, 5% of the 913 HE episodes were
related to benzodiazepines, 4% to opioids and 1% to hypno-
tics. Similarly, another study showed that benzodiazepine use
for 3 to 10 days increased the risk of developing HE by fivefold
[75]. A number of pathophysiological mechanisms for neuro-
toxicity have been proposed: (1) a higher permeability of the
blood-brain barrier (BBB), (2) an increased density or affinity of
certain receptors in the brain, and (3) an increase in circulating
neurotoxins such as ammonia.
The theory of increased BBB permeability is supported by
a recent study by Weiss and colleagues, in which several drugs
and metabolites were found in the cerebrospinal fluid (CSF) of
14 patients with HE that were not present in the CSF of
controls [76]. Indeed, a doubled CSF to serum ratio of cimeti-
dine is seen in cirrhosis [77]. Both results suggest that medi-
cines accumulate in the brain. The reason for the increased
BBB permeability is not well understood. It has been sug-
gested that high exposure to bilirubin results in down-
regulated or occupied efflux pumps (i.e. P-glycoprotein and
multi-drug-resistance protein-1) [76].
With regard to the receptor theory, at comparable
(unbound) plasma levels of benzodiazepines, excessive
sedation was noted in cirrhotics compared to controls [78–
80]. Benzodiazepine levels in the CSF were not higher than
those in controls [81]. Another study demonstrated an
increased density of one type of benzodiazepine receptor
(‘peripheral-type’) in the brain of deceased patients with HE
[82]. The receptor binds, amongst others, benzodiazepine-like
drugs. The upregulation is possibly induced by inflammation
[83]. Activation leads to the synthesis of neurosteroids that can
modulate the gamma-aminobutyric acid (GABA) receptor sys-
tem, and has been linked to the pathogenesis of HE [83].
A third possible mechanism for neurotoxicity in cirrhosis is
the medicine-induced increase of neurotoxins. It has been
demonstrated that certain substances (e.g. ammonia, lactate,
and manganese) are toxic for the brain [84]. Higher levels of
these neurotoxins due to medicine use could contribute to HE.
For example, acetazolamide increases the excretion of bicar-
bonate in the urine, thereby decreasing ammonia excretion.
Several studies describe HE occurrence in patients with cirrho-
sis using acetazolamide that is not explained by the progres-
sion of the underlying disease [85–87]. This mechanism may
further contribute to the impaired BBB theory, as ammonia
can only cross this barrier at high levels [88]. In addition,
ammonia can contribute to neuroinflammation [84], thereby
possibly also affecting neuroreceptors. This example demon-
strates that the mechanism underlying the neurotoxicity of
medicines in patients with cirrhosis is probably multifactorial
and requires further research.
3.2.3. Immunological effects
Patients with cirrhosis are often in a state of immune dysfunc-
tion due to a number of factors (e.g. increased mucosal per-
meability of the gastrointestinal tract, reduced activity of
hepatic reticuloendothelial cells) [89,90]. Immunosuppressive
therapy (such as interferon-α) may exacerbate this state.
Indeed, a higher prevalence of infections has been noted in
cirrhotic patients on interferon-α therapy compared to healthy
controls [91,92]. In one of these studies, 3 of 26 patients (12%)
developed a severe infection [91] and in the other, 9 patients
(28%) developed a bacterial infection after interferon-α ther-
apy [92]. PPIs have also been associated with an increased risk
of infections and spontaneous bacterial peritonitis in patients
with cirrhosis [16]. This effect is likely driven by the increase in
gastric pH, which could lead to bacterial colonization, over-
growth, and translocation [93].
3.2.4. Hematological effects
Due to their disease, patients with cirrhosis frequently have
alterations in baseline hematological parameters. Portal hyper-
tension can lead to hypersplenism and a lower platelet count
[94,95], and hepatic impairment is associated with reduced
synthesis of hematopoietic growth factors (thrombopoietin
and erythropoietin) and coagulation factors (procoagulants
and anticoagulants) [96,97]. One study has also indicated
that patients with cirrhosis lack the appropriate compensatory
increase in thrombopoietin in response to thrombocytope-
nia [98].
Several medicines (e.g. azathioprine, interferon-α, ribavirin)
have been linked to hematotoxicity in patients with cirrhosis.
Two studies have demonstrated that the risk of
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(hematological) toxicity with azathioprine is significantly
increased in cirrhosis [99,100]. In one of these, 75% of 61
patients with cirrhosis developed cytopenia compared to
33% of 114 non-cirrhotic patients [100]. The other was
a case–control study among 86 patients with autoimmune
hepatitis of which 26% suffered from azathioprine toxicity
and 74% did not [99]. In the first group, 55% of patients had
underlying cirrhosis, while this was only 30% of patients in
the second group. Of note, azathioprine is also metabolized by
the liver and PK could therefore also alter in cirrhosis [101].
Interferon-α could also provoke mild bone marrow suppres-
sion and in patients with cirrhosis, decreases in platelets and
leukocytes were more marked compared to patients without
cirrhosis [102]. In a randomized trial of 60 patients with viral
hepatitis treated with interferon-α, 22% of the 23 patients with
cirrhosis developed neutropenia or thrombocytopenia,
whereas only 5% of 37 patients without cirrhosis developed
cytopenias [103]. In another study, 7 (58%) of 12 patients with
chronic viral hepatitis and cirrhosis developed neutropenia or
thrombocytopenia, compared to only 1 (13%) of the 8 patients
without cirrhosis [104].
Ribavirin is also known for inducing hemolytic anemia.
A study among 244 patients with HCV showed that patients
with a lower baseline platelet count experienced
a significantly greater drop in hemoglobin levels [105]. The
29 patients with Child–Pugh A cirrhosis in the study had
a significantly lower baseline platelet count compared to the
215 patients without cirrhosis. The authors describe that not
per se the histological diagnosis of cirrhosis, but its clinical
expression puts patients at risk for more severe ribavirin-
induced hemolytic anemia [105]. To sum up, patients with
cirrhosis often have alterations in hematological parameters
before treatment. This pathophysiologic state could increase
the risk of (severe) hematological toxicity.
The effect of medicines on coagulation in cirrhosis is com-
plex. The hemostatic balance in patients with cirrhosis is very
fragile, partly due to impaired hepatic synthesis of pro- and
anti-coagulation factors [96]. Therefore, patients with cirrhosis
are at risk for both bleeding and thrombotic events [96].
Anticoagulant therapy is further challenged by the large invol-
vement of the liver in the PK of these medicines. In addition,
regular laboratory parameters to monitor the safety and effi-
cacy of therapy (e.g. INR) are often deranged at baseline due
to the changes highlighted above. Overall, anticoagulation
therapy is complex and challenging in patients with cirrhosis
and much is still unknown [96].
3.2.5. Hepatotoxicity
Hepatotoxic effects are not included in Figure 1, because it has
long been assumed that patients with underlying liver disease
are not at an increased risk to experience idiosyncratic drug-
induced liver injury (DILI) compared to healthy patients [106].
It was also assumed that if DILI did occur in these patients, the
consequences would be more severe than in patients without
underlying liver disease [106].
This last assumption was recently confirmed in
a prospective study with data from the United States DILI
network [107]. The mortality rate in patients with underlying
liver disease suffering from DILI (n = 89) was significantly
higher compared to patients without underlying liver disease
(n = 810; 16% versus 5.2%). Remarkably, this study also found
that the incidence of azithromycin DILI was higher in patients
with underlying liver disease (6.7% versus 1.5%), which is in
contrast to the first assumption that these patients do not
have an increased risk of DILI. The authors recommended that
further research is needed because their result could also be
explained by a higher usage of azithromycin in this patient
population.
The greatest difficulty in research on DILI in patients with
underlying liver disease is the distinction between additional
liver injury caused by a medicine or progression of the under-
lying liver disease. In addition, some medicines used for treat-
ing liver diseases have been linked to additional liver injury,
such as some antiviral treatments used for hepatitis C and
obeticholic acid, used in the treatment of primary biliary cho-
langitis [108,109]. In these cases, causality is very difficult to
determine. With regard to HCV treatment, another factor is
possibly involved: a paradoxical response of the liver to virus
clearance [110]. For obeticholic acid, the FDA issued a warning
that several incidents of liver injury and some deaths have
been reported with the use of obeticholic acid in patients with
Child-Pugh B and C cirrhosis [108]. However, this was probably
explained by inadequate prescribing: instead of the once-
weekly dosing in patients with Child-Pugh B and C cirrhosis,
patients were treated with the ‘regular’ once-daily dose [111].
4. Conclusion
Management of patients with cirrhosis is complicated by
alterations in the pharmacology of many medicines that are
indicated for the treatment of liver disease and comorbidities.
The influence of cirrhosis on the PK of a drug depends on both
drug and patient characteristics. Patients with cirrhosis can
exhibit different pharmacological and toxicological responses
to the same drug plasma concentrations compared to patients
without cirrhosis due to pathophysiological changes. Tailored
pharmacotherapy is needed to ensure the safe and appropri-
ate use of medicines in this vulnerable patient group.
5. Expert opinion
The changes in the pharmacology of medicines need to be
considered when prescribing in cirrhosis. Patients with cirrho-
sis often present a complex clinical picture and pharmacother-
apy in these patients can, therefore, be challenging. In this
part, we discuss approaches to implement the knowledge
of PK and PD changes into clinical practice. In addition, we
describe topics for further research.
5.1. Use guidance for prescribing in patients with
cirrhosis
There has been limited guidance to support safe prescribing in
cirrhosis in the past. Advice from the product label about
dosing in hepatic impairment was often unclear, inconsistent,
and recommendations were not specified by the severity of
impairment [112–114]. Several research groups have
attempted to provide health-care professionals with more
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support by publishing reviews on the use of certain medicines
(groups) in cirrhosis [115–118]; however, most remained
vague in their advice (e.g. ‘use with caution’ or ‘dose adjust-
ment needed’) and recommendations were not updated.
To address this lack of guidance, a research project was
started in 2015 to develop freely available medication safety
and dosing recommendations for medicines in patients with
cirrhosis [119]. Data on the safety and pharmacokinetics of
medicines in patients with cirrhosis were collected from the
literature and product labels. Available evidence was reviewed
by a panel of experts, leading to the formation of safety advice
(e.g. can be used, use a safer alternative if possible, or avoid the
use) and dosing advice for 218 medicines (including considera-
tion of the severity of cirrhosis [28]). The safety advice was
based on evidence of additional harm in patients with cirrhosis
compared to healthy controls. Dose adjustments were gener-
ally recommended if the exposure was more than doubled,
thereby considering the therapeutic window of the drug. In
Table 2, an example of the evaluation of non-benzodiazepine
drugs for insomnia (zolpidem and zopiclone) is provided. In
total, over 200 recommendations were developed and pub-
lished in an open access article in 2018 [120]. In this article, all
the safety recommendations can be found with dosing advice,
if applicable. Of the 218 medicines, 31% were classified as
unsafe in (a stage of) cirrhosis and also for 31% of medicines
a dose adjustment was advised [120]. The recommendations
were also published on a free Dutch website: www.geneesmid
delenbijlevercirrose.nl (English example of this website: www.
drugsinlivercirrhosis.org) and integrated into primary care clin-
ical decision support systems (CDSS) in the Netherlands.
Currently, almost 300 recommendations for safe medication
use in patients with cirrhosis have been developed. In supple-
mentary Table 1, an overview is provided of the most important
recommendations for clinical practice.
These recommendations could be useful when prescribing in
patients with cirrhosis, especially to assist non-gastroenterologists.
This is an evolving space, and new researchwill be vital to continue
developing new recommendations to support the safe prescribing
of many more medications and to reinforce the evidence base of
current recommendations. In practice, precaution is needed when
prescribing medicines for which there is currently limited advice,
especially in people with severe cirrhosis (Child-Pugh C), as these
patients are at greatest risk for ADRs associatedwith changes in PK
and PD. Furthermore, clinical indication in some circumstances
may outweigh risks of treatment, and the presence of comorbid-
ities may also influence treatment choice and dosage. This should
be assessed on a case-by-case basis.
5.2. Regularly evaluate pharmacotherapy
The appropriateness and safety of medications can change
with the progression of liver disease, development of new
complications and/or comorbidities over time. A recent
Australian study in a cohort of people with decompen-
sated cirrhosis identified a median of six medication-
related problems per patient (range 2–17) [128]. Almost
half of these problems were judged to be ‘high’ risk for
potential harm to the patient. Examples of problems
included nonadherence (patient-driven due to ADRs), and
drug–drug and drug–disease interactions (often relating to
risk of renal impairment or HE). These are common pro-
blems among patients with cirrhosis [128–132]. The
patient-oriented medication intervention described in the
trial was associated with a reduced incidence rate of
unplanned hospital admissions compared to usual care,
which coincided with 68.9% resolution rate of ‘high’ risk
medication-related problems [128]. This study demon-
strated that it is important to regularly reevaluate pharma-
cotherapy in patients with cirrhosis after prescribing to
ensure the ongoing safe and appropriate use of medica-
tions. Multidisciplinary medication reviews, as often done
in older patients, may be a good model to be followed for
this patient group as well [133]. The implementation of
prescribing information in clinical decision support systems
as highlighted above supports such efforts.
Table 2. Safety and dosing recommendations for the use of zolpidem and zopiclone in patients with cirrhosis, based on the method by Weersink et al. [119] and
retrieved from www.drugsinlivercirrhosis.org.
Zolpidem
Safety class Unsafe (recommended action: avoid the use)
Dosing advice No dosing advice (unsafe)
Evidence: one pharmacokinetic study was retrieved in six patients with cirrhosis (severity unknown) partly described in a pharmacokinetic review [121] and in the
FDA label [122]. The peak plasma levels were doubled in patients with cirrhosis compared to healthy controls and half-life prolonged to 10 hours (2 hours in
controls). The total exposure was fivefold higher in patients with cirrhosis. Regarding safety, we retrieved data on six cases of hepatic encephalopathy associated
with zolpidem identified by the FDA [123], two were described in a case report [124,125]. In a cross-sectional study six more cirrhotic patients had mental
deterioration while using zolpidem [9]. Because of the large pharmacokinetic alterations, the risk of hepatic encephalopathy and the availability of safer
alternatives, zolpidem is classified as ‘unsafe’ in patients with cirrhosis. This is in contrast to the advice from the product information, which only advises to use
one-half of the normal dosage [122].
Zopiclone
Safety class Additional risks known (recommended action: use a safer alternative if available)
Dosing advice Child-Pugh A: start at the lower end of the dosing range
Child-Pugh B: start with half of the normal dose
Child-Pugh C: no dosing advice possible
Evidence: Two studies explored the pharmacokinetics of a single-dose of oral zopiclone in 17 patients with cirrhosis (severity unknown) [126,127]. Bioavailability
increased by 20% in patients with cirrhosis, but peak plasma level were comparable to healthy controls. Half-life was prolonged to 8.5 hours in the two studies
(3.5–5 hours in controls). The exposure to zopiclone was increased by 43% in patients. One of the studies found a negative correlation between serum albumin
and elimination half-life. The pharmacodynamic response was measured in one of these study and psychometric tests were more impaired in cirrhotics than in
controls [126]. Zopiclone is classified as ‘additional risks known’ based on the risk of hepatic encephalopathy. The authors of one study and the product
information advise to start with one-half of the normal dose, i.e. 3.75 mg per day [127]. It is recommend to start at the lower end of the normal dosing range in
Child-Pugh A and to start with half of the normal dose in Child-Pugh B. In patients with Child-Pugh C no data is available and no dosing advice could be given.
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5.3. Further research topics
There are still important gaps in knowledge on the safety and
optimal dose of certain medicines in patients with cirrhosis.
More research is needed on both PK and PD alterations. The
list of medicines classified as having ‘unknown’ safety in (a
stage of) cirrhosis could be used to prioritize this research
[120]. The primary information about alterations in the phar-
macology of medicines in patients with cirrhosis originates
from the pre-marketing PK studies conducted by the pharma-
ceutical industry. In a recent article, we demonstrated that
a large proportion of product labels from recently authorized
medicines contained information on use in hepatic impair-
ment patients [134]. However, we also showed that this infor-
mation was frequently ambiguously formulated and therefore
not per se clinically applicable.
The studies conducted for market authorization concen-
trate on PK, as is also the focus of the regulatory guidelines
[29,30]. Both guidelines do acknowledge that the effect of
medicines could also be different in hepatic impairment and
advise to include efficacy and safety endpoints in the PK
studies when possible [29,30]. Yet, this is limited by the com-
mon design of these PK studies: a small number of patients
(usually around six per severity class and often no patients
with severe cirrhosis) and only a single dose of the study drug
is administered [134]. Toxicological effects could be hard to
detect because of a low frequency or because they resemble
the natural course of cirrhosis [135]. As a result, it is likely that
alterations in the effects are not yet revealed during these pre-
marketing studies. Larger studies with a longer follow-up are
needed, which are usually performed in the post-marketing
setting.
In this post-marketing phase, experimental research is
warranted (e.g. PK studies and randomized controlled trials).
However, performing these studies is complicated by diffi-
culties in recruiting enough relatively healthy cirrhosis sub-
jects and by ethical concerns of research in such a patient
group (especially in people with Child-Pugh C cirrhosis) [11].
As such, post-marketing information mostly results from clin-
ical practice (e.g. spontaneous reporting, case-reports and
case-series) and observational research. In particular for
these types of research, a few things are important to con-
sider. Firstly, when evaluating additional medication harm in
patients with cirrhosis, two questions are specifically rele-
vant: (1) is the noticed effect an ADR or a complication of
cirrhosis? and (2) is the effect more common in patients with
cirrhosis than in healthy controls? To best answer these
questions, a control group of patients with cirrhosis and
one of the healthy controls is desired. Secondly, it is also
important to discriminate between medication harm due to
an overdose (PK alterations) or due to an increased suscept-
ibility (PD alterations). For example, in a study among
patients with severe hepatic dysfunction, a higher frequency
of leukopenia occurred in patients that used β-lactam anti-
biotics, compared to patients using other antibiotics [136].
The authors reported that this was probably caused by
excessive serum concentrations, although these were not
measured, and proposed dose reductions for β-lactam
antibiotics in these patients. However, as previously dis-
cussed, patients with cirrhosis can be more susceptible to
hematotoxicity. As efficacy is essential for antibiotics, dose
adjustment should only be advised when PK data (i.e.
(unbound) plasma levels) are available. Lastly, it would be
very helpful for clinical practice to gain more knowledge on
the prevalence, risk factors and outcome of ADRs in patients
with cirrhosis to better support their clinical decision-making
for the vulnerable patient with cirrhosis.
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